SATSUMA PHARMACEUTICALS, INC. (STSA) News

SATSUMA PHARMACEUTICALS, INC. (STSA): $3.60

0.32 (+9.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add STSA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter STSA News Items

STSA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest STSA News From Around the Web

Below are the latest news stories about Satsuma Pharmaceuticals Inc that investors may wish to consider to help them evaluate STSA as an investment opportunity.

Satsuma Pharmaceuticals (STSA) Gets a Hold Rating from Leerink Partners

In a report issued on December 17, Marc Goodman from Leerink Partners maintained a Hold rating on Satsuma Pharmaceuticals (STSA – Research Report), with a price target of $5.00. The company's shares closed last Wednesday at $4.65. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Avadel Pharmaceuticals. Currently, the analyst consensus on Satsuma Pharmaceuticals is a Moderate Buy with an average price target of $10.00.

Brian Anderson on TipRanks | December 22, 2021

Short Interest in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Drops By 17.7%

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 373,400 shares, a decline of 17.7% from the November 15th total of 453,900 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average daily trading volume, of […]

Transcript Daily | December 21, 2021

Goldman Sachs Group Inc. Increases Holdings in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA)

Goldman Sachs Group Inc. lifted its position in shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) by 27.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,930 shares of the financial services providers stock after acquiring an additional 4,721 shares during the quarter. Goldman [] The post Goldman Sachs Group Inc. Increases Holdings in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) appeared first on ETF Daily News .

ETF Daily News | December 13, 2021

Millennium Management LLC Acquires 126,853 Shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA)

Millennium Management LLC grew its holdings in shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) by 849.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 141,783 shares of the financial services providers stock after acquiring an additional 126,853 shares during the quarter. []

Dakota Financial News | December 11, 2021

Insider Buying: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Major Shareholder Buys 2,922 Shares of Stock

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) major shareholder Commodore Capital Lp purchased 2,922 shares of the businesss stock in a transaction dated Wednesday, November 24th. The shares were purchased at an average cost of $5.42 per share, for a total transaction of $15,837.24. The transaction was disclosed in a document filed with the SEC, which can be []

Dakota Financial News | December 1, 2021

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Major Shareholder Acquires $17,544.00 in Stock

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) major shareholder Commodore Capital Lp bought 3,225 shares of the firms stock in a transaction on Friday, November 19th. The shares were purchased at an average price of $5.44 per share, for a total transaction of $17,544.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, []

Dakota Financial News | November 23, 2021

Vanguard Group Inc. Boosts Holdings in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA)

Vanguard Group Inc. increased its stake in shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) by 204.5% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 644,301 shares of the financial services providers stock after buying an additional 432,741 shares during the quarter. Vanguard Group Inc.s holdings in Satsuma Pharmaceuticals were worth $4,542,000 as of its []

Transcript Daily | November 22, 2021

Satsuma Pharmaceuticals (NASDAQ:STSA) Earns Hold Rating from SVB Leerink

Satsuma Pharmaceuticals (NASDAQ:STSA)‘s stock had its “hold” rating restated by investment analysts at SVB Leerink in a research note issued to investors on Sunday, Analyst Price Targets reports. They currently have a $5.00 price target on the financial services provider’s stock. SVB Leerink’s target price would indicate a potential downside of 14.53% from the stock’s […]

Dakota Financial News | November 16, 2021

Satsuma Pharmaceuticals (NASDAQ:STSA) Given “Buy” Rating at Mizuho

Satsuma Pharmaceuticals (NASDAQ:STSA)‘s stock had its “buy” rating reissued by equities research analysts at Mizuho in a research report issued on Wednesday, AnalystRatings.com reports. They currently have a $15.00 price objective on the financial services provider’s stock. Mizuho’s target price would indicate a potential upside of 140.38% from the stock’s previous close. Separately, Zacks Investment […]

Transcript Daily | November 10, 2021

Satsuma Pharmaceuticals EPS beats by $0.09

No summary available.

Seeking Alpha | November 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5333 seconds.